

# Klaus Brasso

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/747638/publications.pdf>

Version: 2024-02-01

127  
papers

2,522  
citations

218677

26  
h-index

243625

44  
g-index

128  
all docs

128  
docs citations

128  
times ranked

3774  
citing authors

#	ARTICLE	IF	CITATIONS
1	Open vs robot-assisted radical cystectomy (BORARC): a double-blind, randomised feasibility study. <i>BJU International</i> , 2022, 130, 102-113.	2.5	19
2	Prescription rates for commonly used drugs before and after a prostate cancer diagnosis. <i>Cancer Causes and Control</i> , 2022, , 1.	1.8	2
3	A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative Transrectal Ultrasound Biopsy with Long-Term Followup. <i>Journal of Urology</i> , 2022, 208, 100-108.	0.4	10
4	Reply by Authors. <i>Journal of Urology</i> , 2022, , 101097JU0000000000000249103.	0.4	0
5	Diagnostic Age, Age at Death and Stage Migration in Men Dying with or from Prostate Cancer in Denmark. <i>Diagnostics</i> , 2022, 12, 1271.	2.6	0
6	Characteristics of Patients in SPCG-15: A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer. <i>European Urology Open Science</i> , 2022, 41, 63-73.	0.4	3
7	Prescription rates for drugs used in treatment of benign prostatic hyperplasia and erectile dysfunction before and after prostate cancer diagnosis. <i>Acta Oncologica</i> , 2022, 61, 931-938.	1.8	1
8	Risk of Depression After Radical Prostatectomy: A Nationwide Registry-based Study. <i>European Urology Oncology</i> , 2021, 4, 601-608.	5.4	13
9	Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2021, 62, 354-359.	5.0	16
10	Vitamin D levels and the risk of prostate cancer and prostate cancer mortality. <i>Acta Oncologica</i> , 2021, 60, 316-322.	1.8	20
11	Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice. <i>European Urology Open Science</i> , 2021, 24, 25-33.	0.4	4
12	Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance. <i>Cancers</i> , 2021, 13, 1290.	3.7	17
13	The impact of positive surgical margins on salvage radiation or androgen deprivation therapy following radical prostatectomy: a nationwide study. <i>Acta Oncologica</i> , 2021, 60, 620-626.	1.8	0
14	Short-term morbidity and mortality following radical cystectomy: a systematic review. <i>BMJ Open</i> , 2021, 11, e043266.	1.9	48
15	Safety and Effects of Football in Skeletal Metastatic Prostate Cancer: a Subgroup Analysis of the FC Prostate Community Randomised Controlled Trial. <i>Sports Medicine - Open</i> , 2021, 7, 27.	3.1	7
16	Basal Cell Carcinoma of Prostate With MSMB-NCOA4 Fusion and a Probable Basal Cell Carcinoma In Situ: Case Report. <i>International Journal of Surgical Pathology</i> , 2021, 29, 850-855.	0.8	4
17	Temporal changes in cause-specific death in men with localised prostate cancer treated with radical prostatectomy: a population-based, nationwide study. <i>Journal of Surgical Oncology</i> , 2021, 124, 867-875.	1.7	1
18	Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer. <i>European Urology Open Science</i> , 2021, 28, 1-8.	0.4	17

#	ARTICLE	IF	CITATIONS
19	Risk of depression after diagnostic prostate cancer workup—A nationwide, registry-based study. <i>Psycho-Oncology</i> , 2021, 30, 1939-1947.	2.3	7
20	Detection of Clinically Significant Prostate Cancer by Systematic TRUS-Biopsies in a Population-Based Setting Over a 20 Year Period. <i>Urology</i> , 2021, 155, 20-25.	1.0	4
21	Efficacy of dexamethasone in reducing the postembolisation syndrome in men undergoing prostatic artery embolisation for benign prostatic hyperplasia: protocol for a single-centre, randomised, double-blind, placebo-controlled trial—the DEXAPAE™ study. <i>BMJ Open</i> , 2021, 11, e047878.	1.9	1
22	Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study. <i>Cancer Causes and Control</i> , 2020, 31, 139-151.	1.8	3
23	Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1413-1421.	13.7	226
24	Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners. <i>Journal of Cancer Survivorship</i> , 2020, 15, 536-545.	2.9	2
25	Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial. , 2020, 8, e001157.		28
26	AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy. <i>Diagnostics</i> , 2020, 10, 520.	2.6	1
27	The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer. <i>Diagnostics</i> , 2020, 10, 877.	2.6	2
28	Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients. <i>PLoS ONE</i> , 2020, 15, e0238814.	2.5	4
29	Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome. <i>Scientific Reports</i> , 2020, 10, 10704.	3.3	8
30	What is the risk of prostate cancer mortality following negative systematic TRUS-guided biopsies? A systematic review. <i>BMJ Open</i> , 2020, 10, e040965.	1.9	4
31	Characteristics of finasteride users in comparison with nonusers: A Nordic nationwide study based on individual-level data from Denmark, Finland, and Sweden. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 453-460.	1.9	0
32	Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis. <i>European Radiology</i> , 2019, 29, 287-298.	4.5	98
33	Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells. <i>American Journal of Pathology</i> , 2019, 189, 2377-2388.	3.8	16
34	Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis. <i>Journal of Clinical Pathology</i> , 2019, 72, 696-704.	2.0	5
35	Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial. <i>PLoS Medicine</i> , 2019, 16, e1002936.	8.4	30
36	Educational level and the risk of depression after prostate cancer. <i>Acta Oncologica</i> , 2019, 58, 722-729.	1.8	15

#	ARTICLE	IF	CITATIONS
37	Prognostic implication of gait function following treatment for spinal cord compression in men diagnosed with prostate cancer. <i>Scandinavian Journal of Urology</i> , 2019, 53, 222-228.	1.0	1
38	Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e814-e821.	1.9	12
39	Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1405-1412.	2.0	21
40	Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men. <i>British Journal of Cancer</i> , 2019, 120, 1067-1074.	6.4	9
41	Prostate Artery Embolization for Lower Urinary Tract Symptoms in Men Unfit for Surgery. <i>Diagnostics</i> , 2019, 9, 46.	2.6	16
42	Finasteride Use and Risk of Male Breast Cancer: A Caseâ€“Control Study Using Individual-Level Registry Data from Denmark, Finland, and Sweden. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 980-986.	2.5	8
43	5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1025.	4.1	4
44	The association between education and risk of major cardiovascular events among prostate cancer patients: a study from the Diet, Cancer and Health study. <i>Acta OncolÃ³gica</i> , 2019, 58, 715-721.	1.8	3
45	Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis. <i>Annals of Internal Medicine</i> , 2019, 170, 443.	3.9	15
46	Educational level and first-time PSA testing in general practice. <i>Scandinavian Journal of Urology</i> , 2019, 53, 275-281.	1.0	9
47	Football Compared with Usual Care in Men with Prostate Cancer (FC Prostate Community Trial): A Pragmatic Multicentre Randomized Controlled Trial. <i>Sports Medicine</i> , 2019, 49, 145-158.	6.5	33
48	Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 595-608.	7.0	55
49	Active Surveillance for Localized Prostate Cancer: Nationwide Observational Study. <i>Journal of Urology</i> , 2019, 201, 520-527.	0.4	21
50	The use of transrectal ultrasound-guided biopsy following the introduction of prostate-specific antigen testing in Denmark: a population-based analysis. <i>Scandinavian Journal of Urology</i> , 2018, 52, 169-173.	1.0	2
51	Trends in incidence and 5â€“year mortality in men with newly diagnosed, metastatic prostate cancerâ€”A populationâ€“based analysis of 2 national cohorts. <i>Cancer</i> , 2018, 124, 2931-2938.	4.1	58
52	The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy. <i>European Urology Focus</i> , 2018, 4, 360-368.	3.1	7
53	Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e181-e192.	1.9	4
54	Active surveillance for localized prostate cancer: update of a prospective single-center cohort. <i>Scandinavian Journal of Urology</i> , 2018, 52, 14-19.	1.0	12

#	ARTICLE	IF	CITATIONS
55	Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review. <i>Scandinavian Journal of Urology</i> , 2018, 52, 1-7.	1.0	9
56	Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries. <i>Cancer Medicine</i> , 2018, 7, 254-260.	2.8	9
57	Reply to M. Nayan et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 629-630.	1.6	0
58	The prognostic impact of incidental prostate cancer following radical cystoprostatectomy: a nationwide analysis. <i>Scandinavian Journal of Urology</i> , 2018, 52, 358-363.	1.0	8
59	SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. <i>Scandinavian Journal of Urology</i> , 2018, 52, 313-320.	1.0	40
60	Predictive value of combined analysis of pro-NGP and ERG in localized prostate cancer. <i>Apmis</i> , 2018, 126, 804-813.	2.0	12
61	Football training over 5 years is associated with preserved femoral bone mineral density in men with prostate cancer. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2018, 28, 61-73.	2.9	19
62	The "Football is Medicine" platform: scientific evidence, large-scale implementation of evidence-based concepts and future perspectives. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2018, 28, 3-7.	2.9	31
63	Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study. <i>Lancet Oncology</i> , The, 2017, 18, 221-229.	10.7	54
64	Socioeconomic position and mortality among patients with prostate cancer: influence of mediating factors. <i>Acta Oncologica</i> , 2017, 56, 563-568.	1.8	21
65	Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer. <i>Journal of Clinical Pathology</i> , 2017, 70, 1063-1068.	2.0	1
66	Improved survival for patients with de novo metastatic prostate cancer in the last 20 years. <i>European Journal of Cancer</i> , 2017, 72, 20-27.	2.8	34
67	Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up. <i>Surgical Oncology</i> , 2017, 26, 21-27.	1.6	8
68	Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy. <i>Scandinavian Journal of Urology</i> , 2017, 51, 464-469.	1.0	12
69	Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study. <i>European Urology Focus</i> , 2017, 3, 646-649.	3.1	72
70	Isolated testicular prostate cancer metastasis. <i>Scandinavian Journal of Urology</i> , 2017, 51, 426-427.	1.0	4
71	The risk of biochemical recurrence for intermediate-risk prostate cancer after radical prostatectomy. <i>Scandinavian Journal of Urology</i> , 2017, 51, 450-456.	1.0	18
72	Diagnostic characteristics of lethal prostate cancer. <i>European Journal of Cancer</i> , 2017, 84, 18-26.	2.8	31

#	ARTICLE	IF	CITATIONS
73	Safety, Dosimetry, and Tumor Detection Ability of <sup>68</sup> Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 379-386.	5.0	58
74	Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3290-3297.	1.6	69
75	Survival trends in patients diagnosed with metastatic prostate cancer: A nationwide analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 171-171.	1.6	0
76	Nationwide analysis: Changes in the natural history of low risk localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 2017, 12-12.	1.6	0
77	Nationwide analysis: Changes in the natural history of low risk localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 12-12.	1.6	0
78	Diagnostic characteristics of men harboring lethal prostate cancer: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 217-217.	1.6	0
79	Danish Prostate Cancer Registry &ndash; methodology and early results from a novel national database. <i>Clinical Epidemiology</i> , 2016, Volume 8, 351-360.	3.0	25
80	The Danish Prostate Cancer Database. <i>Clinical Epidemiology</i> , 2016, Volume 8, 649-653.	3.0	11
81	The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading &quot; a matched&pair analysis. <i>BJU International</i> , 2016, 117, 883-889.	2.5	19
82	Systematic review: does endocrine therapy prolong survival in patients with prostate cancer?. <i>Scandinavian Journal of Urology</i> , 2016, 50, 135-143.	1.0	15
83	Effectiveness of community-based football compared to usual care in men with prostate cancer: Protocol for a randomised, controlled, parallel group, multicenter superiority trial (The FC Prostate) Tj ETQq1 1 0.7843 14 rgBI4Overl	1.0	14
84	Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study. <i>Cancer Causes and Control</i> , 2016, 27, 1067-1079.	1.8	24
85	Prognostic implications of 2005 Gleason grade modification. Population&based study of biochemical recurrence following radical prostatectomy. <i>Journal of Surgical Oncology</i> , 2016, 114, 664-670.	1.7	8
86	Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center. <i>Acta Oncol&amp;sup3gica</i> , 2016, 55, 1456-1460.	1.8	10
87	Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results. <i>Biomarkers in Medicine</i> , 2016, 10, 209-216.	1.4	11
88	Football training in men with prostate cancer undergoing androgen deprivation therapy: activity profile and short-term skeletal and postural balance adaptations. <i>European Journal of Applied Physiology</i> , 2016, 116, 471-480.	2.5	48
89	Anastomotic complications after robot-assisted laparoscopic and open radical prostatectomy. <i>Scandinavian Journal of Urology</i> , 2016, 50, 274-279.	1.0	13
90	A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 291.e1-291.e7.	1.6	10

#	ARTICLE	IF	CITATIONS
91	Patterns of finasteride use in the male populations of four Nordic countries: A cross-national drug utilization study. <i>Scandinavian Journal of Urology</i> , 2016, 50, 220-227.	1.0	4
92	Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study. <i>Annals of Oncology</i> , 2016, 27, 460-466.	1.2	13
93	Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial. <i>Osteoporosis International</i> , 2016, 27, 1507-1518.	3.1	61
94	Effect of a 2-year home-based endurance training intervention on physiological function and PSA doubling time in prostate cancer patients. <i>Cancer Causes and Control</i> , 2016, 27, 165-174.	1.8	45
95	The Movember campaign: Impact on referral patterns and diagnosis of prostate cancer. <i>Scandinavian Journal of Public Health</i> , 2016, 44, 228-232.	2.3	54
96	Quality assessment of prostate cancer reports to the Danish Cancer Registry. <i>Acta Oncologica</i> , 2016, 55, 24-29.	1.8	20
97	The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy. <i>Prostate</i> , 2015, 75, 1499-1509.	2.3	11
98	First-in-human uPAR PET: Imaging of Cancer Aggressiveness. <i>Theranostics</i> , 2015, 5, 1303-1316.	10.0	92
99	Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study. <i>European Journal of Cancer</i> , 2015, 51, 1283-1292.	2.8	18
100	Poor association between the progression criteria in active surveillance and subsequent histopathological findings following radical prostatectomy. <i>Scandinavian Journal of Urology</i> , 2015, 49, 354-359.	1.0	5
101	ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 788-794.	2.0	8
102	Length of life gained with surgical treatment of prostate cancer: A population-based analysis. <i>Scandinavian Journal of Urology</i> , 2015, 49, 275-281.	1.0	2
103	Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. <i>European Urology</i> , 2015, 68, 317-324.	1.9	96
104	Long-term survival update of the Scandinavian Prostate Cancer Group 6 study: Bicalutamide 150 mg daily versus placebo in hormone-naïve, non-metastatic prostate cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2-2.	1.6	1
105	Urokinase plasminogen activator receptor (uPAR) as a novel biomarker in prostate cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 183-183.	1.6	0
106	Community-Based Recreational Football: A Novel Approach to Promote Physical Activity and Quality of Life in Prostate Cancer Survivors. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 5567-5585.	2.6	31
107	ERG Protein Expression in Diagnostic Specimens Is Associated with Increased Risk of Progression During Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2014, 66, 851-860.	1.9	75
108	Biochemical response to enzalutamide therapy in patients with mCRPC following docetaxel and abiraterone treatment. <i>Journal of Clinical Oncology</i> , 2014, 32, 202-202.	1.6	2

#	ARTICLE	IF	CITATIONS
109	Increasing use of radical prostatectomy for lower-risk prostate cancer in Denmark.. Journal of Clinical Oncology, 2014, 32, 149-149.	1.6	0
110	Biochemical response to ketoconazole therapy in post-chemotherapy mCRPC patients.. Journal of Clinical Oncology, 2014, 32, 174-174.	1.6	0
111	Differences in survival from prostate cancer in Denmark, Iceland and Sweden. European Journal of Cancer, 2013, 49, 1984-1992.	2.8	13
112	Prostate cancer in Denmark 1978â€“2009 â€” trends in incidence and mortality. Acta OncolÃ³gica, 2013, 52, 831-836.	1.8	36
113	PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study. Acta OncolÃ³gica, 2013, 52, 1609-1614.	1.8	23
114	Psychological distress following fecal occult blood test in colorectal cancer screening â€” a population-based study. Scandinavian Journal of Gastroenterology, 2010, 45, 1211-1216.	1.5	31
115	Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate, 2006, 66, 503-513.	2.3	112
116	Variations in serum P1NP, BAP and YKL-40 levels after start of treatment for advanced prostate cancer and the relation to prognosis. Journal of Clinical Oncology, 2004, 22, 4734-4734.	1.6	0
117	The need for hospital care of patients with clinically localized prostate cancer managed by noncurative intent: a population based registry study. Journal of Urology, 2000, 163, 1150-4.	0.4	4
118	Lower Urinary Tract Symptoms: A Population Survey Using the Danish Prostatic Symptom Score (DAN-PSS) Questionnaire. Scandinavian Journal of Urology and Nephrology, 1999, 33, 94-99.	1.4	37
119	Morbidity in patients with clinically localized prostate cancer managed with non-curative intent. A population-based caseâ€“control study. Prostate Cancer and Prostatic Diseases, 1999, 2, 253-256.	3.9	2
120	Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: a population based registry study. Journal of Urology, 1999, 161, 524-8.	0.4	2
121	Prostate cancer in Denmark. Incidence, morbidity and mortality. Scandinavian Journal of Urology and Nephrology, Supplement, 1999, 203, 29-33.	0.0	1
122	Seminal plasma PSA in spinal cord injured men: a preliminary report. Spinal Cord, 1998, 36, 771-773.	1.9	17
123	Prostate Cancer in Denmark: A 50-Year Population-Based Study. Journal of Urology, 1998, 160, 1579-1579.	0.4	0
124	Revision of a Patient-Weighted Symptom Score in Prostatism. Scandinavian Journal of Urology and Nephrology, 1994, 28, 71-75.	1.4	21
125	The â€œWallstentâ€” A New Stent for the Treatment of Urethral Strictures. Scandinavian Journal of Urology and Nephrology, 1993, 27, 247-250.	1.4	12
126	Long-term results of surgery for incarcerated groin hernia. Acta Chirurgica Scandinavica, 1989, 155, 583-5.	0.2	21



#	ARTICLE	IF	CITATIONS
127	Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	8